Time New York: Sun 22 Sep 19:07 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?

Zacks

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Crinetics Pharmaceuticals, Inc. CRNX, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in CRNX.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen four estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.92 per share a month ago to its current level of a loss of $2.05 per share.

Also, for the current quarter, Crinetics Pharmaceuticals has seen two downward estimate revisions versus one revision in the opposite direction, dragging the consensus estimate down to a loss of 54 cents per share from a loss of 49 per share over the past 30 days.


The stock also has seen some pretty dismal trading lately, as the share price has dropped 12.7% in the past month.

Crinetics Pharmaceuticals, Inc. Price and Consensus

So, it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long-time horizon to wait.

If you are still interested in the Medical – Drugs industry, you may instead consider a better-ranked stock – FibroGen, Inc FGEN. The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.